Plaquenil, a medication widely used to treat malaria and certain autoimmune diseases, has been in the spotlight recently due to its potential side effects on eye health. As of 2023, updated guidelines emphasize the importance of regular eye exams for patients taking Plaquenil (hydroxychloroquine) to monitor and mitigate potential retinal damage. Let's delve into the Plaquenil eye exam guidelines for 2023, ensuring you stay informed and proactive about your eye health.

Hydroxychloroquine, sold under the brand name Plaquenil among others, has been a staple in treating malaria and conditions like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). However, long-term use has been linked to retinal toxicity, which can lead to vision loss if left unchecked. The American Academy of Ophthalmology (AAO) and the American Academy of Dermatology (AAD) have collaborated to provide updated guidelines for Plaquenil eye exams in 2023.

Understanding Plaquenil Retinopathy
Plaquenil retinopathy is a progressive condition that affects the retina, the light-sensitive layer at the back of the eye. It typically begins in the macula, the part of the retina responsible for central vision. Early detection is crucial to prevent permanent vision loss, making regular eye exams imperative for patients taking Plaquenil.

Symptoms of Plaquenil retinopathy may include difficulty reading, decreased central vision, and difficulty adapting to darkness. However, these symptoms may not appear until significant damage has occurred, emphasizing the importance of regular eye exams that can detect changes before they become apparent to the patient.
Risk Factors for Plaquenil Retinopathy

Several factors increase the risk of developing Plaquenil retinopathy. Understanding these risk factors can help patients and healthcare providers determine the frequency and type of eye exams needed. Key risk factors include:
- Daily dose of Plaquenil exceeding 5.0 mg/kg of actual body weight
- Duration of treatment exceeding 5 years
- Age over 60
- Pre-existing retinal disease or family history of retinal disease
- Other medications that affect the retina
Patients with one or more of these risk factors may need more frequent eye exams or additional testing.

Plaquenil Eye Exam Guidelines for 2023
The AAO and AAD recommend that patients taking Plaquenil should have a comprehensive eye exam before starting the medication and at regular intervals thereafter. The frequency of these exams depends on the patient's risk factors and the results of previous exams.
For patients with no risk factors, an initial baseline exam is recommended within the first year of starting Plaquenil. Subsequent exams should be performed every 12 months. For patients with one or more risk factors, an initial baseline exam is recommended within the first year, followed by exams every 6 months.

What to Expect During a Plaquenil Eye Exam
A comprehensive eye exam for Plaquenil patients typically includes a detailed medical history, visual acuity testing, dilated fundus exam, and special testing such as fundus autofluorescence (FAF) imaging and multifocal electroretinography (mfERG).




















During the exam, the ophthalmologist will dilate your pupils to examine the back of your eye, focusing on the retina and macula. Special testing, like FAF and mfERG, can help detect early signs of retinal damage that may not be visible during a standard exam.
Fundus Autofluorescence (FAF) Imaging
FAF imaging is a non-invasive test that uses a special camera to take pictures of the retina. It can help detect early changes in the retina that may not be visible with other testing methods. FAF is recommended as an adjunctive test for patients taking Plaquenil, especially those with risk factors for retinopathy.
During FAF imaging, a low-intensity blue light is shone into the eye, exciting fluorescent molecules in the retina. The camera then captures the fluorescent light emitted by these molecules, creating an image of the retina. Abnormalities in the pattern of fluorescence can indicate early retinal damage.
Multifocal Electroretinography (mfERG)
mfERG is an electrophysiological test that measures the electrical activity of the retina in response to light stimulation. It can help detect functional changes in the retina that may not be visible on clinical exam or with other imaging tests.
During mfERG testing, a contact lens electrode is placed on the surface of the eye, and a series of light stimuli are presented to the retina. The electrical responses generated by the retina are then recorded and analyzed. Abnormal mfERG responses can indicate early retinal dysfunction, even in the absence of visible structural changes.
As we move forward in 2023, it's crucial for patients taking Plaquenil to stay proactive about their eye health. Regular eye exams, as guided by the updated Plaquenil eye exam guidelines, can help detect and manage potential retinal damage, preserving your vision for years to come. Don't wait – schedule your comprehensive eye exam today and take the first step towards maintaining your eye health while on Plaquenil.